Table 1.

Biologic agents for RA listed according to licensed and NICE-approved status in different clinical scenarios

	MTX tolerant		MTX intolerant
Scenario	NICE approved	Licensed options	NICE approved	Licensed options
DMARD-IR	Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab	Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, abatacept, tocilizumab	Adalimumab, certolizumab pegol, etanercept	Adalimumab, certolizumab pegol, etanercept, tocilizumab
DMARD-IR, anti-TNF contraindication		Abatacept, tocilizumab		Tocilizumab
Anti-TNF intolerant	Alternative from adalimumab, certolizumab pegol, etanercept, golimumab, infliximab	Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, abatacept, rituximab, tocilizumab	Alternative from adalimumab, certolizumab pegol, etanercept	As DMARD-IR
Anti-TNF ineffective	Rituximab	As anti-TNF intolerant	Alternative from adalimumab, etanercept	As DMARD-IR
Anti-TNF ineffective, rituximab contraindication	Adalimumab, etanercept, infliximab, abatacept, tocilizumab	As DMARD-IR	Alternative from adalimumab, etanercept	As DMARD-IR
Rituximab intolerant	As anti-TNF ineffective, rituximab contraindication	As DMARD-IR	Not applicable	Not applicable
Rituximab ineffective	Tocilizumab	As DMARD-IR	Not applicable	Not applicable